News Releases

2017

Occlutech obtains European CE Mark for its novel PmVSD Occluder (05.04.2017)

Schaffhausen, Switzerland - Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder. The device is a specifically designed implant indicated for the minimally invasive closure of perimembranous ventricular septal defects...

2016

Occlutech obtains European CE mark approval for its LAA Occluder (02.06.2016)

Schaffhausen, Switzerland -Occlutech, a leading innovator of implants to treat structural heart disease,today announced that it has obtained European CE Mark approval for its Left Atrial Appendix, (LAA), occluder. The device is a specifically designed implant for theminimally invasive closure of the LAA, a procedure that minimizes the risk of strokes in patients suffering from atrial fibrillation...

Occlutech awarded by Frost & Sullivan (10.05.2016)

Frost & Sullivan Applauds Occlutech’s Commitment to Customer-focused Innovation and a Broad Product Range of Minimally-invasive Structural Heart Devices...

Early experience of percutaneous paravalvular leak closure using a novel Occlutech occluder (29.02.2016)

Paravalvular regurgitation is an important complication of mitral valve replacement. Although surgical repair is mostly recommended, it is associated with significant morbidity. On the other hand, percutaneous closure is a less invasive alternative approach...

Occlutech obtains Japanese MHW Approval for its ASD Closure Device (12.01.2016)

Schaffhausen, Switzerland - Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained Japanese MHW approval for its dedicated Atrial Septal Defect Closure Device. The device is a specifically designed implant indicated for the minimally invasive closure of Atrial Septal Defects, ASD...

2015

Occlutech obtains European CE Approval for its VSD Closure Device (02.11.2015)

Schaffhausen, Switzerland - Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained European CE Mark approval for its dedicated muscular Ventricle Septal Defect Closure Device, (VSD). The deviceis a specifically designed implant indicated for the minimally invasive closure of muscular Ventricle Septal Defects, VSD...

Occlutech obtains European CE Approval for its novel mVSD Device (29.10.2015)

Schaffhausen, Switzerland - Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained European CE Mark approval for its dedicated muscular Ventricle Septal Defect Closure Device, (VSD). The device is a specifically designed implant indicated for the minimally invasive closure of muscular Ventricle Septal Defects, VSD...

2014

Occlutech launches ASD and PFO occluders in South Korea (26.11.2014)

Jena, Germany - Occlutech, a leading European innovator of products to treat structural heart disease today announced that it is making its range of PFO and ASD occluders available on the South Korean market...

Occlutech PLD (12.05.2014)

I ́m excited to share with you the very first success stories using the Occlutech PLD Occluder for paravalvular leak closure.The Occlutech PLD Occluder is the first CE marked device which offers an alternative treatment for paravalvular leak closure in patients after surgical Mitral & Aortic Valve replacement...

2013

Occlutech wins Invalidation of St Jude Patent (23.07.2013)

Occlutech, a leading European developer of minimally invasive implants for therapy in structural heart disease, today announced that it has successfully obtained a ruling by the U.K. Patents Court in the High Court of Justice in London, that invalidates AGA/St Jude ́s patent -EP0957773B1 in the UK...

Occlutech wins Swedish Appeal Court Ruling against AGA St Jude Medical (27.03.2013)

Occlutech International AB, a leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable judgement from the Appeal Court in Stockholm, Sweden in the on-going patent litigation with AGA/St Jude Medical...

Occlutech Group Acquires NonWoTecc Medical GmbH (12.01.2013)

Schaffhausen, Switzerland January 12, 2013 - Occlutech Holding AG today announced it has successfully completed the all-share acquisition of NonWoTecc Medical GmbH, a privately-held nanotechnology company based in Cologne, Germany...

2012

Occlutech wins the 2012 Excellence in Medtech Award (17.10.2012)

The European Tech Tour Association, an independant, not-for-profit organization committed to the development of emerging technology companies from Europe, announced that it has selected Occlutech to receive the 2012 Excellence in Medtech Award...

2011

Occlutech wins patent ruling against St Jude-AGA Medical in Italy (28.10.2011)

Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy...

Occlutech wins German Supreme Court ruling against AGA / St. Jude Medical (12.05.2011)

Occlutech GmbH, a leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced that it has received a favourable court ruling from the German Supreme Court, (BGH), in Karlsruhe, Gerrmany in patent litigation initiated by AGA Medical Inc., now part of St. Jude Medical Inc...

Occlutech wins Swedish court ruling against AGA-St Jude Medical (04.03.2011)

Occlutech International AB, a leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable judgement from the Appeal Court in Stockholm, Sweden in the on-going patent litigation with AGA/St Jude Medical...